| __timestamp | ADMA Biologics, Inc. | CRISPR Therapeutics AG |
|---|---|---|
| Wednesday, January 1, 2014 | 4823869 | 5114000 |
| Thursday, January 1, 2015 | 6745968 | 13403000 |
| Friday, January 1, 2016 | 8494742 | 31056000 |
| Sunday, January 1, 2017 | 18092835 | 35845000 |
| Monday, January 1, 2018 | 22502922 | 48294000 |
| Tuesday, January 1, 2019 | 25910757 | 63488000 |
| Wednesday, January 1, 2020 | 35050817 | 88208000 |
| Friday, January 1, 2021 | 42896889 | 102802000 |
| Saturday, January 1, 2022 | 52458024 | 102464000 |
| Sunday, January 1, 2023 | 59020000 | 76162000 |
| Monday, January 1, 2024 | 72977000 |
Infusing magic into the data realm
In the ever-evolving biotech industry, understanding the financial dynamics of companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: ADMA Biologics, Inc. and CRISPR Therapeutics AG, from 2014 to 2023. Over this period, CRISPR Therapeutics AG consistently outpaced ADMA Biologics in SG&A spending, peaking in 2021 with expenses nearly doubling those of ADMA. However, by 2023, ADMA Biologics showed a remarkable 22% increase in SG&A expenses compared to 2022, closing the gap with CRISPR, which saw a 26% decrease from its 2021 peak. This shift highlights ADMA's aggressive expansion strategy, while CRISPR's reduction may indicate a strategic pivot or efficiency improvements. Investors and industry analysts should watch these trends closely as they reflect broader strategic shifts within these companies.
SG&A Efficiency Analysis: Comparing Gilead Sciences, Inc. and CRISPR Therapeutics AG
Breaking Down SG&A Expenses: Zoetis Inc. vs CRISPR Therapeutics AG
Summit Therapeutics Inc. and ADMA Biologics, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Ascendis Pharma A/S and CRISPR Therapeutics AG
Alpine Immune Sciences, Inc. vs ADMA Biologics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for ADMA Biologics, Inc. and Rhythm Pharmaceuticals, Inc.
ADMA Biologics, Inc. and Xenon Pharmaceuticals Inc.: SG&A Spending Patterns Compared
ADMA Biologics, Inc. vs Ligand Pharmaceuticals Incorporated: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing ADMA Biologics, Inc. and BioCryst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? CRISPR Therapeutics AG or Amicus Therapeutics, Inc.
CRISPR Therapeutics AG or Taro Pharmaceutical Industries Ltd.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: CRISPR Therapeutics AG vs Evotec SE